INKT

MiNK Therapeutics, Inc.

1.04 USD
+0.03 (+2.97%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MiNK Therapeutics, Inc. stock is up 19.54% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 May’s closed higher than April. 100% of analysts rate it a buy.

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.